Physician profile
Karty Dormera
NPI 1033970322
$1,499.19
in general payments reported to CMS, 2019-2025
29 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,011 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $164.84 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $132.52 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $125.16 | 2024-2025 | |
| Organon LLC | $124.60 | 2024-2025 | Nexplanon |
| Corcept Therapeutics | $107.32 | 2024 | Korlym |
| Amgen INC. | $93.87 | 2024 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $82.91 | 2024 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $65.89 | 2025 | Sunosi, Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $63.93 | 2024 | |
| Astellas Pharma US INC | $63.10 | 2024-2025 | Veozah |
| Biogen, INC. | $60.46 | 2025 | Zurzuvae |
| Pfizer INC. | $59.71 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $49.72 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Vanda Pharmaceuticals INC. | $28.33 | 2024 | Fanapt |
| Seqirus USA INC | $26.87 | 2025 | Flucelvax, Fluad |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $26.03 | 2025 | Activ.A.C., Prevena |
| Sanofi-Aventis U.S. LLC | $22.32 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.61 | 2024 | Rexulti |
| Shield Therapeutics INC | $20.60 | 2025 | |
| Sanofi Pasteur INC. | $20.59 | 2024 | |
| Exeltis, USA INC. | $19.38 | 2025 | Slynd |
| Lundbeck LLC | $17.66 | 2024 | Rexulti |
| Ironwood Pharmaceuticals, INC | $15.87 | 2024 | |
| Medtronic, INC. | $15.42 | 2024 | Minimed 780g |
| Exact Sciences Corporation | $14.80 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $14.57 | 2024 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2024 | Eliquis |
| Vertex Pharmaceuticals Incorporated | $13.87 | 2025 | |
| Innovation Technologies INC | $13.83 | 2025 | Irrisept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karty Dormera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.